---
title: "Nomura raises WUXI XDC's target price to 87.73 yuan, expects profit to rise by 47% this year"
description: "Nomura has raised the target price for WUXI XDC to HKD 87.73, expecting a 47% increase in profits by 2026. Although the revenue and profit forecasts for 2025 have been lowered by 4.5% and 8.7% respect"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275696057.md"
published_at: "2026-02-12T03:33:20.000Z"
---

# Nomura raises WUXI XDC's target price to 87.73 yuan, expects profit to rise by 47% this year

> Nomura has raised the target price for WUXI XDC to HKD 87.73, expecting a 47% increase in profits by 2026. Although the revenue and profit forecasts for 2025 have been lowered by 4.5% and 8.7% respectively, the revenue for 2026 is expected to increase by 37% year-on-year to RMB 8.1 billion, mainly benefiting from more projects entering the clinical trial phase. The gross margin is expected to expand to 36.5%, and the operating profit margin will rise to 29.3%

Nomura has lowered the revenue and profit forecasts for WuXi XDC (02268.HK) for 2025 by 4.5% and 8.7% respectively, reflecting the actual data released by the company last month.

Looking ahead to 2026, revenue is expected to increase by 37% year-on-year to RMB 8.1 billion, roughly in line with market expectations, as more projects enter the later stages of clinical trial applications, which will accelerate revenue growth in this segment. At the same time, the bank expects revenue from commercialized projects to be RMB 181 million, while revenue from the acquisition of Dongyao Pharmaceutical (01875.HK) is expected to be RMB 150 million.

In terms of profit, the bank anticipates a 47% increase in earnings for 2026; the gross profit margin is expected to expand by 0.7 percentage points year-on-year to 36.5%, based on economies of scale, although depreciation from the Singapore facility will have a slight drag; the operating profit margin is expected to expand by 1.1 percentage points year-on-year to 29.3%, reflecting improved efficiency. The bank has raised the target price for WuXi XDC from HKD 82.72 to HKD 87.73, maintaining a "Buy" rating

### Related Stocks

- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [02268.HK - WUXI XDC](https://longbridge.com/en/quote/02268.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 野村證券將藥明合聯開曼的目標價從 82.72 港元上調至 87.73 港元，並維持買入評級 | 野村將藥明合聯（WuXi XDC Cayman）的目標價從 82.72 港元上調至 87.73 港元，維持 “買入” 評級 | [Link](https://longbridge.com/en/news/275736820.md) |
| 藥明合聯開曼表示，預計全年收入將增長超過 45% | 藥明合聯開曼公司：預計財年收入將增長超過 45%，預計財年淨利潤將增長超過 38% | [Link](https://longbridge.com/en/news/272576507.md) |
| 簡訊：藥明合聯發盈喜 料去年盈利增 38% | 藥明合聯生物技術有限公司預計 2025 年全年收入同比上升 45%，淨利潤增 38%，主要因優化產品及服務利潤率和有效成本控制。公司還提出以每股 4 港元收購東曜藥業，總額約 27.9 億港元，收購價較停牌前高出 60%。藥明合聯股價跌 2 | [Link](https://longbridge.com/en/news/272635750.md) |
| 中金公司維持對藥明合聯開曼公司（2268）的買入評級 | 在昨天發佈的一份報告中，中金公司對藥明合聯（WuXi XDC Cayman, Inc.）維持了買入評級，目標價為 88.00 港元。目前，分析師對藥明合聯的共識評級為強烈買入，平均目標價為 83.59 港元 | [Link](https://longbridge.com/en/news/272788694.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.